BACKGROUND: Family Healthware™, a tool developed by the CDC, is a self-administered web-based family history tool that assesses familial risk for six diseases (coronary heart disease; stroke; diabetes; and colon, breast, and ovarian cancers) and provides personalized prevention messages based on risk. The Family Healthware Impact Trial (FHITr) set out to examine the clinical utility of presenting personalized preventive messages tailored to family history risk for improving health behaviors. PURPOSE: The purpose of this study was to examine the impact of Family Healthware on modifying disease risk perceptions, particularly among those who initially underestimated their risk for certain diseases. DESIGN: A total of 3786 patients were enrolled in a cluster-randomized trial to evaluate the clinical utility of Family Healthware. SETTING/PARTICIPANTS: Participants were recruited from 41 primary care practices among 13 states between 2005 and 2007. MAIN OUTCOME MEASURES: Perceived risk for each disease was assessed at baseline and 6-month follow-up using a single-item comparative risk question. Analyses were completed in March 2012. RESULTS: Compared to controls, Family Healthware increased risk perceptions among those who underestimated their risk for heart disease (15% vs 9%, p<0.005); stroke (11% vs 8%, p<0.05); diabetes (18% vs 11%, p<0.05); and colon cancer (17% vs 10%, p=0.05) but not breast or ovarian cancers. The majority of underestimators did not shift in their disease risk perceptions. CONCLUSIONS: Family Healthware was effective at increasing disease risk perceptions, particularly for metabolic conditions, among those who underestimated their risk. Results from this study also demonstrate the relatively resistant nature of risk perceptions. TRIAL REGISTRATION: This study is registered at clinicaltrials.govNCT00164658.
RCT Entities:
BACKGROUND: Family Healthware™, a tool developed by the CDC, is a self-administered web-based family history tool that assesses familial risk for six diseases (coronary heart disease; stroke; diabetes; and colon, breast, and ovarian cancers) and provides personalized prevention messages based on risk. The Family Healthware Impact Trial (FHITr) set out to examine the clinical utility of presenting personalized preventive messages tailored to family history risk for improving health behaviors. PURPOSE: The purpose of this study was to examine the impact of Family Healthware on modifying disease risk perceptions, particularly among those who initially underestimated their risk for certain diseases. DESIGN: A total of 3786 patients were enrolled in a cluster-randomized trial to evaluate the clinical utility of Family Healthware. SETTING/PARTICIPANTS: Participants were recruited from 41 primary care practices among 13 states between 2005 and 2007. MAIN OUTCOME MEASURES: Perceived risk for each disease was assessed at baseline and 6-month follow-up using a single-item comparative risk question. Analyses were completed in March 2012. RESULTS: Compared to controls, Family Healthware increased risk perceptions among those who underestimated their risk for heart disease (15% vs 9%, p<0.005); stroke (11% vs 8%, p<0.05); diabetes (18% vs 11%, p<0.05); and colon cancer (17% vs 10%, p=0.05) but not breast or ovarian cancers. The majority of underestimators did not shift in their disease risk perceptions. CONCLUSIONS: Family Healthware was effective at increasing disease risk perceptions, particularly for metabolic conditions, among those who underestimated their risk. Results from this study also demonstrate the relatively resistant nature of risk perceptions. TRIAL REGISTRATION: This study is registered at clinicaltrials.govNCT00164658.
Authors: Alfred O Berg; Macaran A Baird; Jeffrey R Botkin; Deborah A Driscoll; Paul A Fishman; Peter D Guarino; Robert A Hiatt; Gail P Jarvik; Sandra Millon-Underwood; Thomas M Morgan; John J Mulvihill; Toni I Pollin; Selma R Schimmel; Michael Edward Stefanek; William M Vollmer; Janet K Williams Journal: Ann Intern Med Date: 2009-12-15 Impact factor: 25.391
Authors: Suzanne M O'Neill; Wendy S Rubinstein; Catharine Wang; Paula W Yoon; Louise S Acheson; Nan Rothrock; Erin J Starzyk; Jennifer L Beaumont; James M Galliher; Mack T Ruffin Journal: Am J Prev Med Date: 2009-06 Impact factor: 5.043
Authors: Harvey J Murff; Neeraja B Peterson; Robert A Greevy; Martha J Shrubsole; Wei Zheng Journal: J Gen Intern Med Date: 2007-01 Impact factor: 5.128
Authors: Amy I Zlot; Mary Pat Bland; Kerry Silvey; Beth Epstein; Beverly Mielke; Richard F Leman Journal: Prev Chronic Dis Date: 2008-12-15 Impact factor: 2.830
Authors: Jennifer S Haas; Heather J Baer; Katyuska Eibensteiner; Elissa V Klinger; Stella St Hubert; George Getty; Phyllis Brawarsky; E John Orav; Tracy Onega; Anna N A Tosteson; David W Bates; Graham Colditz Journal: Am J Prev Med Date: 2016-09-14 Impact factor: 5.043
Authors: Elizabeth S Chen; Elizabeth W Carter; Tamara J Winden; Indra Neil Sarkar; Yan Wang; Genevieve B Melton Journal: J Am Med Inform Assoc Date: 2014-10-21 Impact factor: 4.497
Authors: Catharine Wang; Ananda Sen; Melissa Plegue; Mack T Ruffin; Suzanne M O'Neill; Wendy S Rubinstein; Louise S Acheson Journal: Prev Med Date: 2015-04-19 Impact factor: 4.018
Authors: Shelly R Hovick; Therese B Bevers; Jennifer Irvin Vidrine; Stephanie Kim; Phokeng M Dailey; Lovell A Jones; Susan K Peterson Journal: J Cancer Educ Date: 2017-03 Impact factor: 2.037